VADS
CHECKMATE 651 (CA209-651)
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Paris
CHRISTOPHE LE TOURNEAU
VADS
Javelin HN100 (B9991016)
A Randomized Double-blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck.
Paris
CHRISTOPHE LE TOURNEAU
Gynécologie - Ovaires
ATALANTE
A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.
Paris, Saint-Cloud
MANUEL RODRIGUES, ANNE DONNADIEU
Gynécologie - Ovaires
OReO
A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy.
Paris, Saint-Cloud
Gynécologie - Ovaires
FIRST 3000-03-005/ENGOT-OV44
A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)
Paris, Saint-Cloud
VADS
REACH (GORTEC 2017-01)
A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Paris